The chimeric hybrid analgesics are an invention of Chimeracom’s chief science officer, Dr Richard Kream, and the patent covers composition of matter for, and methods of treating pain using novel conjugate molecules (also called chimeric hybrid molecules).
This new family of pharmaceuticals, the Elpis drugs, consists of molecules that conjugate alkaloids (such as morphine) and non-alkaloids. Drugs in the Elpis family produce opioid analgesia with little or no development of opioid tolerance or formation of opioid dependence and are expected to have lower potential for misuse and abuse than other opioid analgesics. The drugs are in preclinical testing.
Chimeracom is engaged in the research and development of novel analgesic drugs that alleviate pain without the adverse side effects of current analgesics, as well as compounds for treating drug abuse.